You are here:

Archived: icatibant (Firazyr)


Following a full submission

icatibant (Firazyr®) is not recommended for use within NHS Scotland for the symptomatic treatment of acute attacks of hereditary angioedema in adults (with C1-esterase-inhibitor deficiency).

Icatibant treatment resulted in symptom relief in patients suffering acute abdominal, cutaneous and/or laryngeal attacks of hereditary angioedema. However, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: icatibant (Firazyr)
SMC Drug ID: 476/08
Manufacturer: Jerini AG
Indication: Hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency)
BNF Category:
Sub Category: 3.5 Respiratory stimulants and pulmonary surfactants
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 10 November 2008

Current Advice

Resubmission 12 March 2012